SCHEMBL2998547

SCHEMBL2998547

COc1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccccc4)cs3)CC2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.72
HSD17B10 Q99714 3/20 0.72
USP2 O75604 2/20 0.72
RECQL P46063 1/20 0.72
LMNA P02545 5/20 0.66
MAPK1 P28482 2/20 0.66
MEN1 O00255 1/20 0.66
KMT2A Q03164 1/20 0.66
ALDH1A1 P00352 6/20 0.65
SMN1; SMN2 Q16637 4/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
MMP1 P03956 1/20 0.64
MMP3 P08254 1/20 0.64
MMP7 P09237 1/20 0.64
MMP9 P14780 1/20 0.64
POLB P06746 2/20 0.62
PKM P14618 2/20 0.60
HPGD P15428 3/20 0.60
KDM4E B2RXH2 2/20 0.60
HTT P42858 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008450 0.94 ALDH1A1 (0.73) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3012013 0.91 MAPT (0.66) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3013984 0.91 MAPT (0.87) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3019541 0.90 SMN1; SMN2 (0.67) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3015774 0.90 SMN1; SMN2 (0.67) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3015112 0.89 SMN1; SMN2 (0.66) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3008149 0.89 SMN1; SMN2 (0.83) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3006945 0.89 SMN1; SMN2 (0.66) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3008688 0.89 SMN1; SMN2 (0.83) MAPTHSD17B10USP2RECQLLMNA
SCHEMBL3001202 0.89 SMN1; SMN2 (0.66) MAPTHSD17B10USP2RECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.